Welcome to our dedicated page for Igm Biosciences news (Ticker: IGMS), a resource for investors and traders seeking the latest updates and insights on Igm Biosciences stock.
IGM Biosciences, Inc. (IGMS) generates news primarily through its clinical-stage biotechnology activities and corporate transactions. The company has described itself as focused on developing engineered IgM-based therapeutic antibodies, including T cell engaging IgM antibodies, for cancer and autoimmune and inflammatory diseases. Its updates often cover progress in clinical trials, strategic shifts in its pipeline, collaboration developments and significant corporate events.
News items have detailed the advancement of key product candidates such as imvotamab, a CD20 x CD3 bispecific IgM T cell engager antibody studied in autoimmune indications including rheumatoid arthritis, systemic lupus erythematosus and idiopathic inflammatory myopathies, and IGM‑2644, a CD38 x CD3 T cell engager antibody in development for autoimmune diseases. Other releases have described clinical studies of aplitabart (also referred to as IGM‑8444), a death receptor 5 agonist evaluated in combination regimens for metastatic colorectal cancer, along with enrollment milestones and trial design features.
Corporate news has included a strategic pivot to focus exclusively on autoimmunity, with an associated pipeline transformation and workforce changes, followed by a later decision to halt further development of imvotamab and IGM‑2644 for autoimmune diseases and to explore internal options and strategic alternatives. IGM Biosciences has also issued announcements about its exclusive worldwide collaboration agreement with Sanofi on IgM antibody agonists for immunology and inflammation targets and other collaborations with biotechnology partners.
A major development in the company’s news flow is the announcement of a definitive merger agreement under which Concentra Biosciences, LLC will acquire IGM Biosciences through a cash tender offer and subsequent merger, with IGM Biosciences becoming a wholly owned subsidiary of Concentra. For readers following IGMS, the news stream provides context on the evolution of the company’s IgM antibody pipeline, its strategic decisions and the transaction that led to its acquisition.
IGM Biosciences (Nasdaq: IGMS) has reported preliminary results from its Phase 1 trial of IGM-2323, a bispecific IgM antibody targeting CD20 x CD3, at the ASH Annual Meeting. Out of 14 patients treated, 9 demonstrated tumor size reduction, with 2 achieving complete responses (CRs) after treatment at the 50/100 mg dose level. The study continues to evaluate escalating doses, aiming for an optimal dosing strategy. IGM-2323 appears well-tolerated, with no severe toxicities reported, suggesting a potentially safer alternative for B-cell malignancy treatment.
IGM Biosciences, a clinical-stage biotechnology firm, will host a conference call and live audio webcast on December 5, 2020, at 2:00 p.m. ET. This event follows the first clinical data presentation of IGM-2323 from their Phase 1 trial at the 62nd American Society of Hematology Annual Meeting. Interested parties can access the call by dialing (866) 649-1996 or (409) 217-8769, using conference ID 1141638. The call will also be available via a live webcast on their website, with a replay accessible for 90 days afterward.
IGM Biosciences, a clinical-stage biotechnology firm, announced that CEO Fred Schwarzer participated in a fireside chat ahead of the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. A recording of this discussion is accessible on the company’s website in the Investors section and will be available for 90 days. IGM Biosciences focuses on developing engineered IgM antibodies and has made significant advancements since 2010 in overcoming challenges related to their therapeutic use.
IGM Biosciences (Nasdaq: IGMS) announced that CEO Fred Schwarzer will present at three investor conferences in November 2020. The conferences are: Stifel Virtual Healthcare Conference on November 16 at 3:20 p.m. ET, Jefferies Virtual London Healthcare Conference on November 17 at 2:20 p.m. ET, and Wolfe Research Healthcare Conference on November 18 at 12:55 p.m. ET. A live webcast will be available on the company’s website, with replays accessible for 90 days after the events.
IGM Biosciences (Nasdaq: IGMS) reported its Q3 2020 results, showing a net loss of $20.3 million, or $0.66 per share, up from a loss of $10.2 million in Q3 2019. Cash and investments decreased to $180.2 million from $236.6 million at year-end 2019. Key updates include initial Phase 1 data presentation for IGM-2323 at the ASH Annual Meeting in December and the initiation of the Phase 1 trial for IGM-8444. IGM also announced a collaboration with AbCellera for novel IgM antibody discovery. The company anticipates 2020 operating expenses of $80-$85 million.
IGM Biosciences (Nasdaq: IGMS) announced the upcoming presentation of initial clinical data for IGM-2323 at the ASH Annual Meeting on December 5, 2020. This bispecific IgM antibody aims to target CD20 on lymphoma cells and CD3 on T cells, presenting a novel approach to treating non-Hodgkin’s lymphoma. The Phase 1 trial has shown positive initial findings, with no dose-limiting toxicities reported among eight patients treated. Preliminary results indicated favorable safety profiles and T cell activation, suggesting potential advantages over traditional therapies.
IGM Biosciences has announced the dosing of the first patient in its Phase 1 clinical trial for IGM-8444, an IgM antibody targeting the DR5 protein in solid cancers and non-Hodgkin’s lymphoma. This multicenter trial will assess the pharmacokinetics, safety, and preliminary efficacy of IGM-8444 as a monotherapy and in combination with chemotherapy. Initial data is expected in 2021. The trial signifies a key milestone for IGM, marking the second program from its IgM antibody platform to enter clinical development.
IGM Biosciences (Nasdaq: IGMS) has announced the dosing of its first patient in a Phase 1 clinical trial for IGM-8444, an IgM antibody targeting DR5 in patients with solid tumors and non-Hodgkin’s lymphoma. The trial aims to assess pharmacokinetics, safety, and preliminary efficacy of IGM-8444, both alone and with chemotherapy. Initial data is expected in 2021. CEO Fred Schwarzer noted the trial's significance as part of IGM's strategy utilizing its proprietary IgM technology platform.
AbCellera and IGM Biosciences (Nasdaq: IGMS) have announced a strategic research collaboration aimed at developing novel IgM antibodies. This multi-year agreement involves AbCellera creating antibody panels for various therapeutic targets identified by IGM, which will then have the rights to develop and commercialize these antibodies. Financial details remain undisclosed. IGM aims to leverage this partnership to enhance its IgM and IgA technology platform, potentially addressing challenges in current therapies. Leadership from both companies expressed optimism regarding the collaboration's impact on therapeutic advancements.
IGM Biosciences, a clinical-stage biotechnology firm, announced that CEO Fred Schwarzer will present at four investor conferences in September 2020. The conferences include:
- Baird 2020 Global Healthcare Conference on September 9 at 3:10 p.m. ET
- H.C. Wainwright 22nd Annual Global Investment Conference on September 16 at 1:00 p.m. ET
- 2020 Cantor Global Virtual Healthcare Conference on September 17 at 4:40 p.m. ET
- Morgan Stanley 18th Annual Global Healthcare Conference on September 18 at 11:45 a.m. ET
Live webcasts will be available on the company's website with a 90-day archive.